This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-10. Anything still debated is marked as such rather than presented as settled.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Biomarkers should be central to the pathophysiological process They should be a ‘‘true’’ surrogate end-point Biomarkers should be stable and vary with disease progression only The severity of the condition should relate to the concentration of the Biomarker Progression should be predicted Effective treatment should show change Even though desmosine can check-off the first three it cannot check off the rest. And this is why research is being done to further the validation of using desmosine as a biomarker for certain diseases like COPD.
A schematic of the optical systems is shown in Figure 1. The variable UV-Vis absorbance detector's optical bench is showing how the flow cell is positioned after the optical system, including the monochromator, which typically has a physical slit and a moving grating, so it is illuminated by a selected wavelength, reaching a photo-diode. The bench of the diode array detector, however, is configured so that the flow cell is positioned before the optical parts, so that the beam containing the entire spectrum is passing through it. The optical parts consist also with a monochromator and a slit, but with a fixed grating, which disperses the light onto a diode array imaging element.
In 2013, United States Representative Tim Murphy introduced the Helping Families in Mental Health Crisis Act, HR2646. The bipartisan bill went through substantial revision and was reintroduced in 2015 by Murphy and Congresswoman Eddie Bernice Johnson. In November 2015, it passed the Health Subcommittee by an 18–12 vote.
== Selected publications == Viswanathan, V.; Mirshad, R. (2023), "Role of Technology for wound Care in Diabetic Foot", Chronic Wound Management, Cham: Springer International Publishing, pp. 67–76, doi:10.1007/978-3-031-26110-7_4, ISBN 978-3-031-26109-1 Viswanathan, Vijay; Ahmed Khan, Balkhiwala; Nachimuthu, Sukanya; Kumpatla, Satyavani (2023). "Precision of Michigan Neuropathy Screening Instrument (MNSI) Tool for the Diagnosis of Diabetic Peripheral Neuropathy Among People with Type 2 Diabetes—A Study from South India". The International Journal of Lower Extremity Wounds. doi:10.1177/15347346231163209. ISSN 1534-7346. "Current and future perspective in the management of diabetes". {{cite journal}}: Cite journal requires |journal= (help) "Type 2 Diabetes Mellitus – The Epidemic Of The 21st Century: The Indian Scenario A Ramachandran, C Snehalatha*, Int. J. Diab. Dev. Countries (1999), Vol. 19". {{cite journal}}: Cite journal requires |journal= (help) High Prevalence of Obstructive Sleep Apnea among People with Type 2 Diabetes Mellitus in a Tertiary Care Center. J Assoc Physicians India. 2017 Nov;65(11):38-42. PMID 29322708. Need for education on footcare in diabetic patients in India. J Assoc Physicians India. 1999 Nov;47(11):1083-5. PMID 10862318. Diabetic nephropathy in type 2 diabetes: the Indian experience. J Assoc Physicians India. 2001 Dec;49:1185-7. PMID 11996441. Prevalence of pathogens in diabetic foot infection in South Indian type 2 diabetic patients. J Assoc Physicians India. 2002 Aug;50:1013-6. PMID 12421021.
This does not replace the refrigeration system but facilitates cooling down of the external machinery. Containers stowed on the exposed upper deck are air-cooled, while those under deck are water-cooled. The water cooling design allows additional refrigerated containers under deck, as water can be used to dissipate the high amount of heat they generate. This system draws fresh water from the ship's water supply, which in turn transfers the heat through heat exchangers to the abundantly available sea water.
Sources: en.wikipedia.org
Porous carbons (PCs) are versatile materials with a wide range of applications, including sensors, actuators, thermal insulation, and energy conversion and supercapacitors. Some examples of PCs are graphene and carbon nanotube-based aerogel. Physical properties that make PCs unique are their low density, high conductivity, mechanical flexibility, and stability in extreme environments.
== Causes == The development of type 2 diabetes is caused by a combination of lifestyle and genetic factors. While some of these factors are under personal control, such as diet and obesity, other factors are not, such as increasing age, female sex, and genetics. Generous consumption of alcohol is also a risk factor. Obesity is more common in women than men in many parts of Africa. The nutritional status of a mother during fetal development may also play a role.
Estrogens, in females, are produced primarily by the ovaries, and during pregnancy, the placenta. Follicle-stimulating hormone (FSH) stimulates the ovarian production of estrogens by the granulosa cells of the ovarian follicles and corpora lutea. Some estrogens are also produced in smaller amounts by other tissues such as the liver, pancreas, bone, adrenal glands, skin, brain, adipose tissue, and the breasts. These secondary sources of estrogens are especially important in postmenopausal women. The pathway of estrogen biosynthesis in extragonadal tissues is different. These tissues are not able to synthesize C19 steroids, and therefore depend on C19 supplies from other tissues and the level of aromatase. In females, synthesis of estrogens starts in theca interna cells in the ovary, by the synthesis of androstenedione from cholesterol. Androstenedione is a substance of weak androgenic activity which serves predominantly as a precursor for more potent androgens such as testosterone as well as estrogen. This compound crosses the basal membrane into the surrounding granulosa cells, where it is converted either immediately into estrone, or into testosterone and then estradiol in an additional step. The conversion of androstenedione to testosterone is catalyzed by 17β-hydroxysteroid dehydrogenase (17β-HSD), whereas the conversion of androstenedione and testosterone into estrone and estradiol, respectively is catalyzed by aromatase, enzymes which are both expressed in granulosa cells.
As of 19 September 2026, at least 234 people had been killed (including 17 who are missing and presumed dead) in 78 strikes on 79 vessels, including 15 vessels struck in the Caribbean Sea, 31 in the Eastern Pacific, and 2 in an unspecified location. In four of the strikes as of 31 December 2025, crew members survived the initial strike. The number of people killed includes two survivors from the initial strike who were killed in subsequent strikes and one missing survivor of the 27 October strike who is presumed dead. Two people who survived the 16 October strike were repatriated to their home countries. The US Coast Guard suspended a search for an unknown number of survivors of the 30 December strike. The Department of Defense has not often provided information about what drug cartels have been involved in the vessels targeted for airstrikes, or publicly identified the alleged drug traffickers.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.